World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Update 2013 on the acute and continuation treatment of unipolar depressive disorders
Top Cited Papers
- 3 July 2013
- journal article
- Published by Informa UK Limited in The World Journal of Biological Psychiatry
- Vol. 14 (5), 334-385
- https://doi.org/10.3109/15622975.2013.804195
Abstract
Objectives. This 2013 update of the practice guidelines for the biological treatment of unipolar depressive disorders was developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal has been to systematically review all available evidence pertaining to the treatment of unipolar depressive disorders, and to produce a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. The guidelines are intended for use by all physicians seeing and treating patients with these conditions. Methods. The 2013 update was conducted by a systematic update literature search and appraisal. All recommendations were approved by the Guidelines Task Force. Results. This first part of the guidelines (Part 1) covers disease definition, classification, epidemiology, and course of unipolar depressive disorders, as well as the management of the acute and continuation phase treatment. It is primarily concerned with the biological treatment (including antidepressants, other psychopharmacological medications, electroconvulsive therapy, light therapy, adjunctive and novel therapeutic strategies) of adults. Conclusions. To date, there is a variety of evidence-based antidepressant treatment options available. Nevertheless there is still a substantial proportion of patients not achieving full remission. In addition, somatic and psychiatric comorbidities and other special circumstances need to be more thoroughly investigated. Therefore, further high-quality informative randomized controlled trials are urgently needed.Keywords
This publication has 196 references indexed in Scilit:
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2013
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2012
- Benefits From AntidepressantsArchives of General Psychiatry, 2012
- The size and burden of mental disorders and other disorders of the brain in Europe 2010European Neuropsychopharmacology, 2011
- Novel melatonin-based therapies: potential advances in the treatment of major depressionThe Lancet, 2011
- A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorderJournal of Affective Disorders, 2010
- Efficacy of an Algorithm-Guided Treatment Compared With Treatment as UsualJournal of Clinical Psychopharmacology, 2009
- A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depressionJournal of Psychiatric Research, 2009
- Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant ActionArchives of General Psychiatry, 2006
- A randomised, controlled study on the effects of a short-term endurance training programme in patients with major depressionBritish Journal of Sports Medicine, 2006